

## **Supplementary information**

**Supplementary Note 1. Functional annotation analysis of major depression disorder and seven localized pain.**

**Supplementary Figure 1. Framework for the bidirectional Mendelian randomization study design of pain and major depression disorder.**

**Supplementary Figure 2. Heat maps showing bi-clustering of traits and cell-types over six histone marks.**

**Supplementary Table 1. Characteristic of the 102 major depression disorder associated instruments.**

**Supplementary Table 2. Characteristic of the 28 headache associated instruments.**

**Supplementary Table 3. Characteristics of the 39 multisite chronic pain associated instruments.**

**Supplementary Table 4. Information and source of GWAS data used for analyses.**

**Supplementary Table 5. Sensitivity analysis using 44 depression associated instruments from a GWAS with minimal sample overlap with UK biobank.**

**Supplementary Table 6. Multivariable Mendelian randomization adjusting for traits likely to confound the depression-pain relationship.**

**Supplementary Table 7. Bi-clustering of traits and cell-types over six histone marks**

### **Supplementary Information 1. Functional annotation analysis of major depression disorder and seven localized pain.**


To understand the (dis)similarity across traits, we further partitioned heritability using stratified-LD score regression (LDSC) leveraging genome-wide genetic variants of pain and MDD [1]. This method partitions SNPs into functional categories and calculates category-specific enrichment based on the assumption that a category of SNPs is enriched for heritability if SNPs with high linkage disequilibrium to that category have higher  $\chi^2$  statistics than SNPs with low linkage disequilibrium to that category.

We performed analyses using 396 annotations (<http://www.roadmapepigenomics.org/overview>) constructed by the Roadmap project from narrow peaks in six chromatin marks, consisting of DNase hypersensitivity, three histone modification marks (H3K4me3, H3K4me1 and H3K36me3), and two acetylation marks (H3K9ac and H3K27ac), in a set of 88 primary cell types / tissues. Each cell-type-specific annotation corresponds to a histone mark in a single cell type (for example, H3K27ac in CD19 immune cells) and there are 396 such annotations in total. The Roadmap annotations is the largest existing epigenomic mapping dataset that contains ~100 cell types and six different chromatin marks. The six chosen marks are core epigenomic marks informative for gene activity and expression – specifically, DNase hypersensitivity denoting regions of accessible chromatin; H3K27ac and H3K9ac associated with increased activation of enhancer and promotor regions; H3K4me3 associated with promotor regions; H3K4me1 associated with enhancer regions; and H3K36me3 associated with transcribed regions [2]. Noteworthily, enhancer associated marks, like H3K27ac which tags both enhancer and promotor activity, are considered more informative for tissue-specific disease enrichment [2].

We further divided those 396 cell-type-specific annotations into 9 broad groups (adipose, central nervous system (CNS), digestive system, cardiovascular, musculoskeletal and connective tissue, immune and blood, liver, pancreas, and other) by taking a union of the cell-type-specific annotations within each group (for example, SNPs with any of the six histone modifications in any hematopoietic and immune cells were considered as one big category). All functional annotation analyses were conducted using the LDSC software [1, 3], and enrichment values were transformed into color scale

and visualized by hierarchical clustering.


**Supplementary Figure 1. Framework for the bidirectional Mendelian randomization study design of pain and major depression disorder.**




SNP: single nucleotide polymorphism; GWAS: genome-wide association study; IV: instrumental variables.


Solid arrows represent the association exists in the framework, while dash arrows indicate the association may exist or not. Green ticks mean the association should be valid for MR assumptions (*relevance*), while red crosses represent that the existence of such association would violate MR assumptions (*exclusion restriction* and *exchangeability*).

**Supplementary Figure 2. Heat maps showing bi-clustering of traits and cell-types over six histone marks.** We performed 396 cell-type-specific annotation analysis in pain at different body sites and in MDD. We compared these enrichment results using a heat map. Each checker reflects the beta coefficient z-score, scaled by traits. Red indicates enrichment, blue indicates depletion. Deeper color represents stronger magnitude of effects. Asterisk represents statistical significance withstood correction ( $P < 0.05/396$ ). The category of cell types is color coded to the left. A) DNase, B) H3K27ac, C) H3K36me3, D) H3K4me1, E) H3K4me3 and F) H3K9ac.













E) H3K4me3



F) H3K9ac



**Supplementary Table 1. Characteristic of the 102 major depression disorder associated instruments.**

SNP	A1	A2	EAF	Beta	SE	P-value	Confounding traits
rs1002656	T	C	0.70	-0.0210	0.0024	4.84E-19	General factor of neuroticism
rs10061069	C	G	0.22	-0.0250	0.0026	5.17E-22	Well-being spectrum (multivariate analysis)
rs10149470	A	G	0.49	-0.0206	0.0021	6.88E-22	Extremely high intelligence, Cognitive ability, Autism
rs1021363	A	G	0.35	0.0226	0.0023	3.77E-23	
rs1045430	T	G	0.48	-0.0226	0.0022	4.44E-25	Neuroticism
rs10774600	T	C	0.17	-0.0133	0.0030	1.07E-05	
rs10789214	T	C	0.57	0.0137	0.0022	3.81E-10	
rs10817969	T	G	0.72	0.0169	0.0024	1.32E-12	
rs10890020	A	G	0.52	-0.0267	0.0022	3.31E-34	
rs10913112	T	C	0.38	-0.0214	0.0023	1.72E-20	
rs1095626	T	C	0.58	-0.0285	0.0022	6.31E-39	
rs11135349	A	C	0.47	-0.0250	0.0022	2.18E-30	
rs113188507	A	G	0.28	0.0234	0.0025	2.94E-21	
rs1152578	T	C	0.44	-0.0152	0.0022	4.19E-12	
rs11579246	A	G	0.91	0.0320	0.0037	8.07E-18	
rs12052908	A	T	0.53	-0.0211	0.0022	3.98E-22	
rs1226412	T	C	0.79	0.0232	0.0027	3.35E-18	
rs12624433	A	G	0.26	0.0191	0.0025	2.16E-14	Neuroticism, Self-reported math ability (MTAG)
rs12923444	A	C	0.56	-0.0237	0.0023	1.76E-24	
rs12966052	C	G	0.18	-0.0187	0.0028	3.76E-11	
rs12967143	C	G	0.70	-0.0256	0.0024	1.61E-27	Well-being spectrum (multivariate analysis)
rs12967855	A	G	0.33	0.0207	0.0023	1.32E-19	Educational attainment (years of education)
rs13084037	A	G	0.77	-0.0217	0.0025	1.79E-17	
rs1343605	A	C	0.38	0.0231	0.0022	1.62E-25	
rs1354115	A	C	0.62	0.0186	0.0022	4.39E-17	
rs1409379	T	C	0.76	0.0164	0.0025	8.26E-11	
rs141954845	A	G	0.39	0.0179	0.0022	1.18E-15	
rs143186028	T	G	0.18	0.0244	0.0028	7.23E-18	
rs1448938	A	G	0.42	0.0172	0.0022	3.74E-15	Gut microbiome composition (winter)
rs1466887	T	C	0.55	-0.0125	0.0022	1.37E-08	
rs1568452	T	C	0.39	0.0293	0.0022	3.08E-40	
rs16887442	T	C	0.43	0.0148	0.0022	1.25E-11	
rs169235	A	G	0.75	-0.0170	0.0025	1.61E-11	Neuroticism
rs17641524	T	C	0.21	-0.0243	0.0027	7.90E-20	Educational attainment (MTAG), Primary biliary cholangitis
rs1890946	T	C	0.47	-0.0194	0.0022	8.62E-19	
rs1933802	C	G	0.45	-0.0198	0.0022	1.36E-19	
rs1956373	T	G	0.74	-0.0169	0.0025	6.08E-12	
rs1982277	T	C	0.76	0.0206	0.0026	1.28E-15	
rs198457	T	C	0.19	-0.0213	0.0028	5.41E-14	Neuroticism, Life satisfaction
rs200949	A	G	0.87	0.0433	0.0034	2.13E-37	
rs2029865	A	T	0.45	-0.0184	0.0022	4.02E-17	
rs2043539	A	G	0.42	0.0220	0.0022	8.32E-24	
rs2187490	T	G	0.91	-0.0152	0.0039	8.49E-05	
rs2247523	C	G	0.53	-0.0159	0.0021	9.05E-14	
rs2509805	T	C	0.32	0.0191	0.0024	4.92E-16	
rs2568958	A	G	0.62	0.0336	0.0022	4.45E-52	Body mass index, weight
rs263645	A	T	0.54	0.0176	0.0022	6.92E-16	
rs2670139	T	C	0.76	-0.0177	0.0025	2.19E-12	
rs2876520	C	G	0.53	-0.0187	0.0022	2.65E-17	Well-being spectrum (multivariate analysis)
rs301799	T	C	0.57	-0.0254	0.0022	4.05E-31	Thyroid peroxidase antibody positivity
rs30266	A	G	0.33	0.0323	0.0023	1.99E-45	loneliness measure
rs3099439	T	C	0.53	-0.0208	0.0022	1.61E-21	Neuroticism
rs3213572	A	G	0.47	0.0196	0.0021	5.51E-20	
rs33431	T	C	0.61	0.0121	0.0022	4.69E-08	
rs34488670	T	C	0.79	-0.0193	0.0027	4.69E-13	Age of smoking initiation (MTAG), Risk-taking tendency

rs34653192	C	G	0.32	-0.0196	0.0024	3.39E-16	
rs34937911	T	C	0.88	0.0244	0.0034	5.39E-13	
rs35553410	T	C	0.75	-0.0159	0.0025	2.18E-10	
rs3793577	A	G	0.47	-0.0211	0.0022	5.58E-22	Neuroticism, Life satisfaction
rs3823624	T	C	0.81	0.0294	0.0028	1.61E-26	Sleep duration
rs4346585	T	C	0.70	-0.0163	0.0024	4.87E-12	
rs45510091	A	G	0.95	0.0463	0.0049	7.74E-21	Feeling miserable
rs4772087	T	C	0.37	0.0209	0.0023	2.34E-20	
rs56314503	T	G	0.75	-0.0203	0.0025	1.28E-16	
rs56887639	A	G	0.73	-0.0171	0.0024	6.04E-13	
rs57344483	A	G	0.93	-0.0241	0.0041	5.26E-09	
rs58104186	A	G	0.47	0.0190	0.0022	3.56E-18	
rs58621819	A	T	0.79	-0.0169	0.0027	2.17E-10	Heel bone mineral density
rs59283172	A	G	0.11	-0.0174	0.0036	1.18E-06	
rs5995992	T	C	0.72	-0.0301	0.0024	2.60E-35	
rs60157091	T	C	0.52	0.0205	0.0022	5.54E-21	Well-being spectrum (multivariate analysis)
rs61902811	A	G	0.37	-0.0289	0.0022	5.17E-39	
rs61990288	A	G	0.51	-0.0249	0.0021	1.96E-31	
rs62091461	T	C	0.23	-0.0199	0.0026	1.75E-14	
rs62188629	A	G	0.31	0.0169	0.0024	6.15E-13	
rs67436663	C	G	0.24	-0.0141	0.0025	2.83E-08	
rs6783233	T	C	0.28	0.0177	0.0024	1.14E-13	
rs7030813	T	C	0.37	0.0251	0.0022	8.88E-30	
rs7117514	A	G	0.54	-0.0166	0.0022	3.64E-14	
rs7193263	A	G	0.67	-0.0206	0.0023	3.83E-19	
rs7198928	T	C	0.62	0.0219	0.0022	3.71E-23	
rs7200826	T	C	0.26	0.0270	0.0025	3.09E-28	Well-being spectrum (multivariate analysis)
rs7227069	A	G	0.43	0.0242	0.0022	2.13E-28	
rs7241572	A	G	0.20	0.0200	0.0027	2.56E-13	
rs725616	T	C	0.36	0.0135	0.0022	1.06E-09	
rs72710803	A	C	0.91	-0.0247	0.0038	1.35E-10	
rs75581564	A	G	0.12	0.0248	0.0034	3.49E-13	
rs7585722	T	C	0.85	-0.0215	0.0030	5.47E-13	
rs7624336	T	G	0.21	0.0092	0.0027	0.000548	
rs7659414	A	C	0.58	-0.0089	0.0022	4.32E-05	
rs7685686	A	G	0.58	0.0173	0.0022	5.52E-15	
rs7758630	A	T	0.41	-0.0165	0.0022	7.79E-14	
rs7807677	T	C	0.55	0.0211	0.0022	5.40E-22	
rs78337797	T	G	0.88	0.0229	0.0034	1.37E-11	
rs7837935	T	G	0.15	-0.0226	0.0031	1.15E-13	Neuroticism
rs7932640	T	C	0.44	0.0227	0.0022	3.40E-25	
rs8037355	T	C	0.56	-0.0192	0.0022	1.52E-18	
rs913930	A	G	0.64	-0.0219	0.0023	1.03E-21	Neuroticism
rs9363467	T	C	0.60	0.0158	0.0023	2.50E-12	
rs9545360	A	C	0.18	-0.0167	0.0029	6.70E-09	
rs9592461	A	G	0.49	0.0243	0.0022	1.17E-28	Well-being spectrum (multivariate analysis)
rs997934	T	C	0.38	0.0163	0.0023	4.60E-13	

SNP: single nucleotide polymorphism; A1: effect allele; A2: other allele; EAF: effect allele frequency.

**Supplementary Table 2. Characteristic of the 28 headache associated instruments.**

SNP	A1	A2	EAF	Beta	SE	P-value	Confounder
rs1011121	G	A	0.59	-0.0080	0.0014	1.46E-08	
rs1050316	T	G	0.65	-0.0098	0.0015	1.54E-11	Platelet count
rs10774231	C	T	0.58	-0.0082	0.0014	4.55E-09	
rs11172113	C	T	0.41	-0.0202	0.0014	4.92E-47	Migraine, Medication use, Coronary artery disease, Lung function (FEV1/FVC)
rs12134493	A	C	0.12	0.0136	0.0021	1.93E-10	Migraine
rs12740679	G	C	0.26	0.0110	0.0016	3.66E-12	
rs1555132	A	C	0.36	0.0083	0.0015	1.16E-08	
rs17220352	G	A	0.24	0.0104	0.0016	9.42E-11	
rs2036465	C	A	0.80	-0.0093	0.0017	4.01E-08	
rs2072806	G	C	0.13	-0.0121	0.0021	5.30E-09	
rs2362290	A	G	0.21	-0.0141	0.0017	6.25E-16	
rs2895526	A	T	0.47	-0.0086	0.0014	4.61E-10	
rs34097149	C	T	0.02	-0.0297	0.0046	1.33E-10	
rs3748784	G	A	0.51	-0.0078	0.0014	1.75E-08	
rs4596713	T	C	0.57	-0.0078	0.0014	2.30E-08	
rs4909945	C	T	0.70	0.0087	0.0015	5.13E-09	Platelet aggregation
rs4941139	C	T	0.34	0.0093	0.0015	2.22E-10	
rs56304645	T	C	0.23	0.0102	0.0016	5.74E-10	
rs56349329	A	G	0.16	-0.0104	0.0019	3.69E-08	
rs6606710	C	T	0.41	0.0084	0.0015	8.44E-09	Neuroticism
rs7300001	G	A	0.08	-0.0144	0.0025	8.86E-09	General cognitive ability
rs7555006	G	A	0.44	0.0081	0.0014	5.87E-09	
rs77804065	T	C	0.22	0.0130	0.0017	5.87E-15	Feeling guilty, Neuroticism
rs78438709	G	A	0.07	-0.0186	0.0027	8.57E-12	
rs8614	A	C	0.18	0.0105	0.0018	4.25E-09	Self-reported math ability, Smoking initiation
rs9349379	G	A	0.40	-0.0110	0.0014	3.59E-15	Migraine, Coronary heart disease, Cervical artery dissection, Alcohol consumption, blood pressure
rs9486715	C	A	0.33	0.0171	0.0015	2.58E-31	
rs9490318	T	C	0.15	0.0124	0.0019	1.72E-10	

SNP: single nucleotide polymorphism; A1: effect allele; A2: other allele; EAF: effect allele frequency.

**Supplementary Table 3. Characteristics of the 39 multisite chronic pain associated instruments.**

SNP	A1	A2	EAF	Beta	SE	P-value	Confounder
9:140251458_g_a	G	A	0.123	-0.0277	0.0037	5.30E-14	
rs10259354	G	A	0.2983	0.0147	0.0026	3.00E-08	
rs10888692	C	G	0.4301	-0.0143	0.0025	5.30E-09	
rs10992729	C	T	0.3344	0.0158	0.0026	1.10E-09	
rs11079993	G	T	0.3825	-0.0173	0.0025	5.70E-12	
rs11599236	T	C	0.4058	0.0138	0.0025	3.30E-08	Depressed affect, Feeling miserable, Neuroticism, Educational attainment
rs11751591	G	A	0.1516	0.0214	0.0034	2.70E-10	
rs11786084	G	A	0.3328	-0.0145	0.0026	2.30E-08	
rs11871043	T	C	0.4213	0.0149	0.0025	1.70E-09	
rs12071912	C	T	0.3163	-0.0153	0.0026	5.30E-09	
rs12435797	G	T	0.1859	-0.0173	0.0031	3.70E-08	
rs12537376	A	G	0.3969	0.0151	0.0025	1.70E-09	
rs12765185	T	A	0.2669	-0.0151	0.0027	3.90E-08	Educational attainment
rs13135092	A	G	0.08071	-0.0328	0.0044	1.50E-13	HDL cholesterol levels, white blood cell count, Insomnia, Alcohol use disorder, Age of smoking initiation
rs13136239	G	A	0.3508	0.0141	0.0026	3.60E-08	Borderline personality disorder
rs1443914	T	C	0.475	0.0162	0.0024	2.80E-11	
rs17474406	G	A	0.01805	-0.0492	0.0088	2.40E-08	
rs1946247	T	G	0.1389	-0.019	0.0035	4.90E-08	
rs197422	C	A	0.3794	-0.015	0.0025	2.00E-09	
rs1976423	A	C	0.4968	-0.014	0.0024	8.20E-09	
rs2006281	C	T	0.4981	0.0135	0.0024	3.40E-08	
rs2183271	T	C	0.3578	-0.014	0.0025	3.10E-08	Educational attainment (MTAG)
rs2386584	T	G	0.3835	-0.0166	0.0025	2.80E-11	
rs2424248	G	A	0.1255	0.023	0.0037	3.70E-10	
rs28428925	G	A	0.1365	-0.0214	0.0035	1.40E-09	
rs285026	G	T	0.4297	-0.0138	0.0025	1.90E-08	
rs34811474	G	A	0.2285	0.0192	0.0029	2.70E-11	Lung function (FVC), General cognitive ability, Intelligence, Educational attainment, Body mass index, Osteoarthritis
rs4852567	A	G	0.2834	0.0149	0.0027	4.30E-08	
rs59898460	T	C	0.4044	0.0169	0.0025	9.20E-12	
rs61883178	C	A	0.1696	-0.0208	0.0033	2.00E-10	
rs62098013	G	A	0.3631	-0.0169	0.0026	4.00E-11	Smoking initiation
rs6478241	A	G	0.365	0.0149	0.0025	3.10E-09	Migraine without aura
rs6770476	C	T	0.289	-0.0154	0.0027	9.40E-09	Neuroticism
rs6869446	T	C	0.3861	-0.0144	0.0025	9.50E-09	
rs6907508	A	G	0.1146	-0.0217	0.0038	1.10E-08	HDL cholesterol levels x alcohol consumption
rs6926377	A	C	0.294	-0.0155	0.0027	7.90E-09	
rs6966540	T	C	0.3762	-0.0139	0.0025	3.30E-08	Heel bone mineral density
rs7628207	T	C	0.1766	0.0195	0.0032	8.40E-10	
rs7798894	A	T	0.2888	0.0153	0.0027	1.60E-08	

SNP: single nucleotide polymorphism; A1: effect allele; A2: other allele; EAF: effect allele frequency.

**Supplementary Table 4. Information and source of GWAS data used for analyses.**

Analyses	Traits	Consortium	Participants	Web source	Inclusion criteria
Main analysis	Major depressive disorder	UK Biobank, 23andMe and Psychiatric Genomics Consortium ( <b>main analysis</b> )	807,553 individuals of European ancestry (246,363 cases and 561,190 controls), of which 361,315 individuals (127,552 cases and 233,763 controls) were from UK Biobank	<a href="https://datashare.is.ed.ac.uk/handle/10283/3203">https://datashare.is.ed.ac.uk/handle/10283/3203</a>	<ol style="list-style-type: none"> <li>1) In UK biobank, case and control status were defined based on the response to the question “Have you ever seen a general practitioner / psychiatrist for nerves, anxiety, tension or depression?”, and individuals were excluded if self-reporting bipolar disorder, schizophrenia, personality disorder or taking antipsychotic medications.</li> <li>2) In 23andMe, MDD was defined based on responses to web-based surveys, with individuals that self-reported as having received a clinical diagnosis or treatment for depression classified as cases.</li> <li>3) In PGC, case and control status were defined based on clinically-derived phenotypes for MDD.</li> </ol>
	Headache	UK Biobank	224,073 individuals of European ancestry (74,761 cases and 149,312 controls)	<a href="https://figshare.com/articles/fourpainphenotypes1/7699556">https://figshare.com/articles/fourpainphenotypes1/7699556</a> <a href="https://figshare.com/articles/fourpainphenotype2/7699583">https://figshare.com/articles/fourpainphenotype2/7699583</a>	Localized pain were defined based the question “In the last month have you experienced any of the following that interfered with your usual activities?”. The options were: 1. headache; 2. facial pain; 3. neck or shoulder pain; 4. back pain; 5. stomach or abdominal pain; 6. hip pain; 7. knee pain; 8. pain all over the body; 9. none of the above; 10. prefer not to say. Cases were those who selected the specific pain site option for the above question, regardless of whether they had selected other options. Controls were those who selected the “none of the above” option.
	Facial pain		151,922 individuals of European ancestry (2,610 cases and 149,312 controls)		
	Neck / shoulder pain		203,306 individuals of European ancestry (53,994 cases and 149,312 controls)		
	Stomach / abdominal pain		157,529 individuals of European ancestry (8,217 cases and 149,312 controls)		
	Back pain		193,303 individuals of European ancestry (4,3991 cases and 149,312 controls)		
	Hip pain		159,428 individuals of European ancestry (10,116 cases and 149,312 controls)		
	Knee pain		171,516 individuals of European ancestry (22,204 cases and 149,312 controls)		
	Multisite chronic pain		387,649 individuals of European ancestry		
Sensitivity analysis	BMI	UK Biobank, GIANT consortium	~700,000 participants of European ancestry	<a href="https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files">https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files</a>	
	Education	Social Science Genetic Association Consortium	1,131,881 individuals of European ancestry	<a href="http://www.thessgac.org/data">www.thessgac.org/data</a> .	
	Exercise	UK Biobank	91,105 participants of European ancestry	<a href="http://biobank.ctsu.ox.ac.uk/crystal/docs.cgi?id=1">http://biobank.ctsu.ox.ac.uk/crystal/docs.cgi?id=1</a>	
	Smoking	GWAS & Sequencing Consortium of Alcohol and Nicotine	1.2 million individuals of European ancestry	<a href="https://genome.psych.umn.edu/index.php/GSCAN">https://genome.psych.umn.edu/index.php/GSCAN</a>	
	Alcohol consumption				
	Major depressive disorder	Psychiatric Genomics Consortium, deCODE, GenScotland, GERA, iPSYCH, UK Biobank and 23andMe ( <b>sensitivity analysis</b> )	480,395 individuals of European ancestry (135,458 cases and 344,901 controls), of which 29,740 individuals (14,260 cases and 15,480 controls) were from UK biobank	<a href="https://www.nature.com/articles/s41588-018-0090-3">https://www.nature.com/articles/s41588-018-0090-3</a>	For majority of the cohorts included in this GWAS, cases were individuals clinically-diagnosed with MDD, while those with other psychiatric disorders, such as bipolar disorder and non-affective psychosis, were excluded from the cases and controls.

**Supplementary Table 5. Sensitivity analysis using 44 depression associated instruments from a GWAS with minimal sample overlap with UK biobank.**

Methods	#SNP	OR (95%CI)	P-value	P-value for intercept / heterogeneity
<b>Multisite chronic pain</b>				
Inverse variance weighted	36	1.13 (1.08-1.18)	<b>4.25E-07</b>	1.46E-08
MR Egger	36	0.98 (0.70-1.36)	0.88	0.40
Weighted median	36	1.10 (1.05-1.16)	<b>2.18E-05</b>	
<b>Headache</b>				
Inverse variance weighted	34	1.04 (1.02-1.07)	<b>6.40E-05</b>	4.61E-03
MR Egger	34	0.98 (0.85-1.14)	0.82	0.43
Weighted median	34	1.04 (1.02-1.07)	<b>7.97E-04</b>	
<b>Neck / shoulder pain</b>				
Inverse variance weighted	36	1.04 (1.02-1.07)	<b>3.43E-05</b>	3.75E-03
MR Egger	36	0.97 (0.84-1.12)	0.66	0.31
Weighted median	36	1.04 (1.02-1.07)	<b>5.58E-04</b>	
<b>Back pain</b>				
Inverse variance weighted	34	1.03 (1.01-1.05)	<b>2.38E-03</b>	4.41E-03
MR Egger	34	1.00 (0.86-1.15)	0.95	0.63
Weighted median	34	1.02 (1.00-1.05)	0.09	
<b>Abdominal / stomach pain</b>				
Inverse variance weighted	36	1.02 (1.01-1.03)	<b>8.31E-05</b>	0.17
MR Egger	36	1.07 (1.00-1.15)	0.05	0.15
Weighted median	36	1.02 (1.00-1.03)	0.01	
<b>Facial pain</b>				
Inverse variance weighted	36	1.00 (0.99-1.01)	0.81	0.08
MR Egger	36	1.00 (0.96-1.05)	0.87	0.84
Weighted median	36	1.00 (1.00-1.01)	0.38	
<b>Hip pain</b>				
Inverse variance weighted	30	1.01 (1.00-1.02)	0.17	0.63
MR Egger	30	1.01 (0.93-1.09)	0.90	0.95
Weighted median	30	1.00 (0.99-1.02)	0.57	
<b>Knee pain</b>				
Inverse variance	36	1.00 (0.98-1.01)	0.76	0.02



weighted				
MR Egger	36	1.09 (0.97-1.22)	0.14	0.13
Weighted median	36	0.99 (0.98-1.01)	0.53	

---

IVW: inverse-variance weighted approach; OR: odds ratio; CI: confidence interval

**Supplementary Table 6. Multivariable Mendelian randomization adjusting for traits likely to confound the depression-pain relationship.**

Methods	# SNP	OR (95%CI)	P-value	P-value for intercept / heterogeneity	# SNP	OR (95%CI)	P-value	P-value for intercept / heterogeneity	# SNP	OR (95%CI)	P-value	P-value for intercept / heterogeneity	# SNP	OR (95%CI)	P-value	P-value for intercept / heterogeneity	# SNP	OR (95%CI)	P-value	P-value for intercept / heterogeneity
BMI			SMOKING			EDUCATION			PHYSICAL ACTIVITY			ALCOHOL CONSUMPTION								
<b>Headache</b>																				
IVW	670	1.00 (0.99-1.01)	0.91	< 0.001	374	<b>1.03 (1.02-1.05)</b>	2.1×10 <sup>-6</sup>	< 0.001	1258	<b>0.90 (0.89-0.91)</b>	1.7×10 <sup>-74</sup>	< 0.001	10	1.00 (0.99-1.02)	0.59	< 0.001	98	<b>0.93 (0.90-0.96)</b>	3.9×10 <sup>-5</sup>	< 0.001
MR-Egger	670	<b>0.93 (0.90-0.96)</b>	2.1×10 <sup>-6</sup>	< 0.001	374	0.99 (0.94-1.04)	0.70	0.12	1258	<b>0.88 (0.85-0.92)</b>	9.1×10 <sup>-11</sup>	0.17	10	1.00 (0.98-1.03)	0.73	0.90	98	<b>0.88 (0.82-0.94)</b>	1.6×10 <sup>-4</sup>	0.05
Weighted median	670	0.99 (0.97-1.00)	0.04		374	<b>1.03 (1.01-1.04)</b>	7.0×10 <sup>-5</sup>		1258	<b>0.91 (0.90-0.92)</b>	2.8×10 <sup>-51</sup>		10	1.00 (0.99-1.003)	0.28		98	<b>0.90 (0.86-0.94)</b>	3.7×10 <sup>-6</sup>	
<b>Neck / shoulder pain</b>																				
IVW	670	<b>1.02 (1.01-1.03)</b>	1.4×10 <sup>-3</sup>	< 0.001	372	<b>1.06 (1.04-1.07)</b>	1.3×10 <sup>-23</sup>	< 0.001	1267	<b>0.89 (0.88-0.90)</b>	3.8×10 <sup>-114</sup>	< 0.001	13	1.00 (0.99-1.01)	0.19	0.07	96	1.02 (0.98-1.05)	0.29	< 0.001
MR-Egger	670	0.98 (0.96-1.01)	0.21	0.01	372	1.02 (0.97-1.06)	0.51	0.07	1267	<b>0.88 (0.85-0.91)</b>	4.2×10 <sup>-13</sup>	0.37	13	1.00 (0.99-1.01)	0.37	0.85	96	0.94 (0.86-1.03)	0.21	0.08
Weighted median	670	1.01 (0.99-1.02)	0.42		372	<b>1.05 (1.04-1.07)</b>	1.1×10 <sup>-13</sup>		1267	<b>0.90 (0.88-0.91)</b>	4.1×10 <sup>-71</sup>		13	1.00 (0.99-1.01)	0.26		96	1.03 (0.99-1.08)	0.19	
<b>Back pain</b>																				
IVW	670	1.01 (1.00-1.02)	0.02	< 0.001	364	<b>1.04 (1.03-1.05)</b>	1.4×10 <sup>-16</sup>	< 0.001	1254	<b>0.92 (0.916-0.93)</b>	2.2×10 <sup>-75</sup>	< 0.001	10	1.00 (0.99-1.01)	0.07	0.92	94	1.03 (0.99-1.06)	0.06	0.005
MR-Egger	670	0.99 (0.97-1.01)	0.45	0.09	364	1.02 (0.98-1.07)	0.26	0.37	1254	<b>0.94 (0.92-0.97)</b>	1.2×10 <sup>-4</sup>	0.15	10	1.00 (0.99-1.01)	0.97	0.55	94	0.99 (0.91-1.09)	0.90	0.39
Weighted median	670	1.00 (0.99-1.01)	0.83		364	<b>1.04 (1.03-1.05)</b>	1.1×10 <sup>-9</sup>		1254	<b>0.92 (0.91-0.94)</b>	1.3×10 <sup>-38</sup>		10	1.00 (0.99-1.01)	0.54		94	1.02 (0.97-1.06)	0.42	
<b>Abdominal / stomach pain</b>																				
IVW	670	1.00 (0.99-1.01)	0.16	0.002	372	<b>1.01 (1.00-1.02)</b>	7.8×10 <sup>-6</sup>	< 0.001	1267	<b>0.98 (0.97-0.99)</b>	1.6×10 <sup>-10</sup>	0.003	13	1.00 (0.99-1.004)	0.72	0.04	96	1.00 (0.99-1.02)	0.63	0.11
MR-Egger	670	0.99 (0.98-1.01)	0.28	0.09	372	0.99 (0.97-1.01)	0.45	0.06	1267	0.99 (0.99-1.01)	0.53	0.21	13	1.00 (0.99-1.005)	0.68	0.44	96	0.94 (0.90-0.99)	0.01	0.004
Weighted median	670	1.00 (0.99-1.01)	0.68		372	<b>1.01 (1.00-1.02)</b>	4.0×10 <sup>-3</sup>		1267	<b>0.99 (0.98-0.995)</b>	1.5×10 <sup>-3</sup>		13	1.00 (0.99-1.004)	0.86		96	1.00 (0.97-1.02)	0.78	
<b>Facial pain</b>																				
IVW	670	1.00 (0.99-1.01)	0.76	0.24	372	<b>1.004 (1.001-1.007)</b>	0.005	< 0.07	1267	<b>0.994 (0.991-0.997)</b>	2.0×10 <sup>-3</sup>	< 0.001	13	1.00 (0.99-1.002)	0.71	0.32	96	0.99 (0.98-1.004)	0.27	0.23
MR-Egger	670	1.00 (0.99-1.01)	0.55	0.44	372	1.01 (0.99-1.02)	0.43	0.90	1267	1.00 (0.99-1.01)	0.55	0.63	13	1.00 (0.99-1.001)	9.34	0.14	96	0.98 (0.96-1.01)	0.15	0.27
Weighted median	670	1.00 (0.99-1.01)	0.87		372	1.00 (1.00-1.01)	0.04		1267	<b>0.99 (0.98-1.00)</b>	0.009		13	1.00 (0.99-1.002)	0.63		96	0.99 (0.98-1.01)	0.28	
<b>Hip pain</b>																				
IVW	670	1.005 (1.00-1.01)	0.03	0.18	372	<b>1.01 (1.006-1.02)</b>	2.4×10 <sup>-5</sup>	0.08	1267	<b>0.98 (0.97-0.99)</b>	2.7×10 <sup>-12</sup>	0.17	13	1.00 (0.99-1.005)	0.93	< 0.001	96	1.00 (0.98-1.02)	0.99	0.18
MR-Egger	670	1.01 (0.99-1.02)	0.31	0.83	372	1.01 (0.99-1.04)	0.23	0.79	1267	0.98 (0.97-1.00)	0.06	0.91	13	1.00 (0.99-1.01)	0.36	0.22	96	0.99 (0.95-1.04)	0.83	0.81
Weighted median	670	1.01 (0.99-1.02)	0.08		372	1.01 (1.00-1.02)	0.02		1267	<b>0.98 (0.97-0.99)</b>	6.3×10 <sup>-7</sup>		13	1.00 (0.99-1.004)	0.87		96	1.01 (0.98-1.04)	0.54	
<b>Knee pain</b>																				
IVW	670	1.00 (0.99-1.01)	0.87	< 0.001	372	<b>1.01 (1.00-1.02)</b>	1.4×10 <sup>-4</sup>	< 0.001	1267	<b>0.97 (0.96-0.98)</b>	5.0×10 <sup>-19</sup>	< 0.001	13	1.00 (0.995-1.004)	0.97	0.31	96	<b>1.03 (1.01-1.05)</b>	0.04	0.07
MR-Egger	670	0.99 (0.97-1.01)	0.46	0.46	372	1.02 (0.98-1.05)	0.35	0.99	1267	<b>0.95 (0.93-0.98)</b>	1.7×10 <sup>-4</sup>	0.20	13	1.00 (0.993-1.007)	0.99	1.00	96	0.98 (0.92-1.05)	0.62	0.18
Weighted median	670	1.00 (0.99-1.01)	0.57		372	1.01 (0.99-1.02)	0.17		1267	<b>0.97 (0.96-0.98)</b>	8.2×10 <sup>-12</sup>		13	1.00 (0.99-1.002)	0.40		96	1.03 (0.99-1.07)	0.14	

IVW: inverse-variance weighted approach; OR: odds ratio; CI: confidence interval

## Reference

1. Finucane HK, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, Loh P-R, Anttila V, Xu H, Zang C, Farh K, Ripke S, Day FR, Purcell S, Stahl E, Lindstrom S, Perry JRB, Okada Y, Raychaudhuri S, Daly MJ, Patterson N, Neale BM, Price AL, ReproGen C, Schizophrenia Working Group of the Psychiatric Genomics C, The RC. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet.* 2015;47(11):1228-35.
2. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, Amin V, Whitaker JW, Schultz MD, Ward LD, Sarkar A, Quon G, Sandstrom RS, Eaton ML, Wu Y-C, Pfenning A, Wang X, Claussnitzer Yaping Liu M, Coarfa C, Alan Harris R, Shores N, Epstein CB, Gjoneska E, Leung D, Xie W, David Hawkins R, Lister R, Hong C, Gascard P, Mungall AJ, Moore R, Chuah E, Tam A, Canfield TK, Scott Hansen R, Kaul R, Sabo PJ, Bansal MS, Carles A, Dixon JR, Farh K-H, Feizi S, Karlic R, Kim A-R, Kulkarni A, Li D, Lowdon R, Elliott G, Mercer TR, Neph SJ, Onuchic V, Polak P, Rajagopal N, Ray P, Sallari RC, Siebenthall KT, Sinnott-Armstrong NA, Stevens M, Thurman RE, Wu J, Zhang B, Zhou X, Abdennur N, Adli M, Akerman M, Barrera L, Antosiewicz-Bourget J, Ballinger T, Barnes MJ, Bates D, Bell RJA, Bennett DA, Bianco K, Bock C, Boyle P, Brinchmann J, Caballero-Campo P, Camahort R, Carrasco-Alfonso MJ, Charnecki T, Chen H, Chen Z, Cheng JB, Cho S, Chu A, Chung W-Y, Cowan C, Athena Deng Q, Deshpande V, Diegel M, Ding B, Durham T, Echipare L, Edsall L, Flowers D, Genbacev-Krtolica O, Gifford C, Gillespie S, Giste E, Glass IA, Gnirke A, Gormley M, Gu H, Gu J, Hafler DA, Hangauer MJ, Hariharan M, Hatan M, Haugen E, He Y, Heimfeld S, Herlofsen S, Hou Z, Humbert R, Issner R, Jackson AR, Jia H, Jiang P, Johnson AK, Kadlec T, Kamoh B, Kapidzic M, Kent J, Kim A, Kleinewietfeld M, Klugman S, Krishnan J, Kuan S, Kutayavin T, Lee A-Y, Lee K, Li J, Li N, Li Y, Ligon KL, Lin S, Lin Y, Liu J, Liu Y, Luckey CJ, Ma YP, Maire C, Marson A, Mattick JS, Mayo M, McMaster M, Metsky H, Mikkelsen T, Miller D, Miri M, Mukame E, Nagarajan RP, Neri F, Nery J, Nguyen T, O'Geen H, Paithankar S, Papayannopoulou T, Pelizzola M, Plettner P, Propson NE, Raghuraman S, Raney BJ, Raubitschek A, Reynolds AP, Richards H, Riehle K, Rinaudo P, Robinson JF, Rockweiler NB, Rosen E, Rynes E, Schein J, Sears R, Sejnowski T, Shafer A, Shen L, Shoemaker R, Sigaroudinia M, Slukvin I, Stehling-Sun S, Stewart R, Subramanian SL, Suknuntha K, Swanson S, Tian S, Tilden H, Tsai L, Urich M, Vaughn I, Vierstra J, Vong S, Wagner U, Wang H, Wang T, Wang Y, Weiss A, Whitton H, Wildberg A, Witt H, Won K-J, Xie M, Xing X, Xu I, Xuan Z, Ye Z, Yen C-a, Yu P, Zhang X, Zhang X, Zhao J, Zhou Y, Zhu

J, Zhu Y, Ziegler S, Beaudet AE, Boyer LA, De Jager PL, Farnham PJ, Fisher SJ, Haussler D, Jones SJM, Li W, Marra MA, McManus MT, Sunyaev S, Thomson JA, Tlsty TD, Tsai L-H, Wang W, Waterland RA, Zhang MQ, Chadwick LH, Bernstein BE, Costello JF, Ecker JR, Hirst M, Meissner A, Milosavljevic A, Ren B, Stamatoyannopoulos JA, Wang T, Kellis M, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, Amin V, Whitaker JW, Schultz MD, Ward LD, Sarkar A, Quon G, Sandstrom RS, Eaton ML, Wu Y-C, Pfenning AR, Wang X, Claussnitzer M, Liu Y, Coarfa C, Harris RA, Shores N, Epstein CB, Gjoneska E, Leung D, Xie W, Hawkins RD, Lister R, Hong C, Gascard P, Mungall AJ, Moore R, Chuah E, Tam A, Canfield TK, Hansen RS, Kaul R, Sabo PJ, Bansal MS, Carles A, Roadmap Epigenomics C, Integrative analysis c, Integrative analysis l, Data p, processing l, Integrative analysis c-l, Analysis, production c, Co-principal i, Scientific program m, Principal i. Integrative analysis of 111 reference human epigenomes. *Nature*. 2015;518(7539):317-30.

3. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM, Schizophrenia Working Group of the Psychiatric Genomics C. Ld score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47(3):291-95.